Catheter Precision, Inc. (VTAK) is a publicly traded Healthcare sector company. As of May 21, 2026, VTAK trades at $0.79 with a market cap of $2.23M and a P/E ratio of -0.05. VTAK moved -3.83% today. Year to date, VTAK is -61.62%; over the trailing twelve months it is -85.28%. Its 52-week range spans $0.75 to $33.06. Rallies surfaces VTAK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in VTAK news today?
Catheter Precision Divests Atherectomy Tech for $15,000 and 5% Equity Stake: Catheter Precision agreed to sell its atherectomy catheter technologies, including FDA approvals and patents, for $15,000 upfront, a 5% equity stake with anti-dilution protection up to $5M, and 10-year royalties. The divestiture sharpens focus on its electrophysiology platform as shares trade 21% below their 20-day SMA.
COLOMBATTO MARTIN J sold 3 (~$1.201) on Jan 29, 2025.
JENKINS DAVID A bought 9.53K (~$5.69K) on Jan 23, 2024.
JENKINS DAVID A bought 9.53K (~$4.09K) on Jan 22, 2024.
VTAK Analyst Consensus
VTAK analyst coverage data. Average price target: $0.00.
Common questions about VTAK
What changed in VTAK news today?
Catheter Precision Divests Atherectomy Tech for $15,000 and 5% Equity Stake: Catheter Precision agreed to sell its atherectomy catheter technologies, including FDA approvals and patents, for $15,000 upfront, a 5% equity stake with anti-dilution protection up to $5M, and 10-year royalties. The divestiture sharpens focus on its electrophysiology platform as shares trade 21% below their 20-day SMA.
Does Rallies summarize VTAK news?
Yes. Rallies summarizes VTAK news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is VTAK research on Rallies investment advice?
No. Rallies provides research, data, and educational context for VTAK. It does not provide personalized investment advice.
